ApoGlyx’s Post

IntraBio is pleased to announce that The New England Journal of Medicine (NEJM Group) has published the landmark results of the Phase 3, Pivotal Trial with our lead compound IB1001 for the treatment of Niemann-Pick disease Type C (NPC). In this randomized, double-blind, placebo-controlled, Pivotal Phase III trial, IB1001 showed a statistically significant improvement in neurological signs and symptoms, functioning, and quality of life in pediatric and adult NPC patients versus placebo. IB1001 was well-tolerated, with no serious adverse reactions. https://lnkd.in/eqA2MACY

📢 Exciting Research Alert! 🌟 Cureus Journal of Medical Science, part of Springer Nature Group, proudly presents a groundbreaking study on the effectiveness of SGLT2 inhibitors vs. Pioglitazone in treating Non-Alcoholic Fatty Liver Disease (NAFLD) or Non-Alcoholic Steatohepatitis (NASH). This systematic review sheds light on promising treatments for these widespread liver conditions. 💡 Dive into the research to explore innovative approaches to managing NAFLD and NASH. 📚 🔗 Read the full article here: https://lnkd.in/em9aT-9h

🌟 Navigating In Vivo Hemolysis in Evans Syndrome 🌟 Evans syndrome, a rare autoimmune disorder where the body attacks its own red blood cells and platelets, presents significant clinical challenges. Recently, Natividad Rico, Alison Bransfield, Caroline M, Joyce, Mary R Cahill, Michelle O'Shaughnessy, and Seán Costelloe managed a complex case involving a female patient with Evans syndrome admitted with severe anemia and jaundice. Despite multiple therapies, biochemistry samples showed persistently elevated hemolytic index (HI) levels due to ongoing complement-mediated hemolysis. Many test results were blocked as "sample hemolyzed," complicating her management. To address this, a novel laboratory algorithm for the timely release of critical biochemical values, accompanied by interpretative comments was designed. This facilitated prompt, informed decisions by the clinical team. This case underscores the importance of preparing for ongoing in vivo hemolysis and the need for innovative reporting strategies. Timely, interpretative results from skilled laboratory personnel are crucial for effective patient management. 🧪🤝 Read the full article: https://lnkd.in/dzsvzUd6 #healthcare #laboratoryscience #patientcare #medicalinnovation #medicalresearch

Today, the #NEJM (New England Journal of Medicine) published a critically important first clinical study of the presence of micro and nanoplastics (MNP) in carotid arterial plaques, and its impact on cardiovascular health. The findings are worrisome! ⤵️ Among the 257 patients enrolled who underwent excision of carotid plaques, and had post-surgical follow up for 34 months, the investigators detected: 🔎 polyethylene micro/nanoparticles in 58.4% of the patients, which were lodged in their cellular tissue; 🔎 polyvinyl chloride (PVC) micro/nanoparticles in 12% of the patients. 🔎 patients who had MNPs detected had 4.5-fold higher risk toward a composite of myocardial infarction, stroke, or death from any cause at 34 months of follow-up, than those in whom MNPs were not detected. 📌 Whether entering by inhalation or ingestion, MNPs have been found in the tissue and organs of all humans; this study has provided a first indication of the toxicity and harmful health impact of MNPs on cardiovascular health. 🔗 This Recent 2024 review about the harmful health effects of MNPs was discussed in The Lancet (https://lnkd.in/g_HPE8qk?) #microplastics #nanoplastics #publichealth #plasticpollution

https://lnkd.in/dXH27s8v Coconut water is anti-inflammatory, can manipulate the gut microbiome and is a rich source of potassium. Gut microbiome modulation improves outcomes in UC, and potassium possesses in vitro anti-inflammatory property. We evaluated the effect of coconut water as an adjunct therapy for patients with mild-moderate UC.

How Does the Kynurenine Pathway Influence Long COVID? I'm thrilled to announce that our review paper on the role of the kynurenine pathway in COVID-19 neuropathogenesis and its impact on long COVID has been published! 🧠 This paper explores how alterations in the kynurenine pathway might contribute to the neurological symptoms experienced by long COVID patients. Understanding these mechanisms could be key to developing targeted therapies for long COVID. Check out the full paper here: https://lnkd.in/gXE-Cdhn

https://lnkd.in/dWEWiU-n Our SRMA just published in EUSjournal shows that the novel EndoRotor device seems to be safe and effective for treating pancreatic necrosis. Patients undergoing endoscopic necrosectomy with the EndoRotor seem to require less debridement sessions when compared with studies using conventional instruments. * Seven studies (79 patients) included. * The pooled rate of clinical success was 96% (91%-100%) with a pooled technical success rate of 96% (91%-100%). * The pooled procedure-related adverse event rate was 8% (2%-14%), which included procedure-associated bleeding, pneumoperitoneum, peritonitis, pleural effusion, and dislodgement of lumen-apposing metal stents. Daryl Ramai, Zohaib Ahmed Saurabh Chandan MD, FACP Smit Deliwala MD Yaseen Alastal Ali Nawras Marcello Fabio Maida Monique T Barakat Andrea Anderloni Douglas G. Adler, MD

When administered to your body, ozone saturates tissues with oxygen, regulates the immune system, decreases inflammation, and promotes healing. It is also toxic to bacteria, viruses, fungi, and cancer cells but harmless to normal cells. See how ozone therapy works here: https://lnkd.in/gq-VUtNn 

Our department chair, Opeolu Adeoye, MD, MS, recently led a large multi-center national NIH funded clinical trial entitled Multi-arm Optimization of Stroke Thrombolysis (MOST). The goal of the trial was to test the efficacy of adding argatroban (a blood thinner) or eptifibatide (inhibits blood platelets from sticking together) to the routine standard-of-care intravenous thrombolysis treatment for patients experiencing an acute ischemic stroke.      Dr. Adeoye’s team found that these two adjunct anti-coagulant medications were ineffective at improving post-treatment outcomes for stroke patients. The results of this important trial will help contribute to the impact of future stroke trials. The findings are now available in The New England Journal of Medicine.    Learn more: https://lnkd.in/gA2jmgtY

post stroke cognitive recovery